Skip to content
Bending the Curve Trial by Trial
?

A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2

Phase 3NCT00004067

Population
Women with surgically removed HER2-positive breast cancer
Design
Randomised trial of doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks, with or without trastuzumab; the first joint analysis with NCCTG N9831 is reported in the same paper (see trial b31-n9831-joint).
Arms
  • Group 1 (control): Doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks
  • Group 2 (experimental): The same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel
People
Romond EH
Primary publication: Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. PubMedDOI

Appears in

Sources

  1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84.

    PubMedDOI